The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
Open accessAbstract
BACKGROUND: A recombinant canarypox vector expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pro, and membrane-linked gp120 (vCP1521), combined with a bivalent gp120 protein boost (AIDSVAX B/E), provided modest protection against HIV-1 infection in a community-based population in Thailand (RV144 trial). No protection was observed in Thai injection drug users who received AIDSVAX B/E alone (Vax003 trial). We compared the neutralizing antibody response in these 2 trials. METHODS: Neutralization was assessed with tier 1 and tier 2 strains of virus in TZM-bl and A3R5 cells. RESULTS: Neutralization of several tier 1 viruses was detected in both RV144 and Vax003. Peak titers were higher in Vax003 and waned rapidly in both trials. The response in RV144 was targeted in part to V3 of gp120.vCP1521 priming plus 2 boosts with gp120 protein was superior to 2 gp120 protein inoculations alone, confirming a priming effect for vCP1521. Sporadic weak neutralization of tier 2 viruses was detected only in Vax003 and A3R5 cells. CONCLUSION: The results suggest either that weak neutralizing antibody responses can be partially protective against HIV-1 in low-risk heterosexual populations or that the modest efficacy seen in RV144 was mediated by other immune responses, either alone or in combination with neutralizing antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034
Self-citationAntibody neutralization and escape by HIV-1
Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., et al. (2003) · Nature · doi:10.1038/nature01470 · Cited by 2,421
Self-citationBuchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
Self-citationThe HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens
Wyatt, R., & Sodroski, J. (1998) · Science · doi:10.1126/science.280.5371.1884 · Cited by 1,598
Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569 · cited 1×
“TZM-bl is a genetically engineered HeLa cell line (also known as JC53-BL) that expresses CD4, CCR5, and CXCR4 [27] and carries Tat-regulated reporter genes for firefly Luc and Escherichia coli β-galactosidase under regulatory control of an HIV1 long-terminal-repeat sequence [28].”
BackgroundSelf-citationMascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S., Birx, D. L., et al. (2000) · Nature Medicine · doi:10.1038/72318 · Cited by 1,250
Platt, E. J., Wehrly, K., Kuhmann, S. E., Chesebro, B., & Kabat, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.4.2855-2864.1998 · Cited by 1,219
Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K. M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10108-10125.2005 · Cited by 1,070
Self-citationRapid cloning of high-affinity human monoclonal antibodies against influenza virus
Wrammert, J., Smith, K., Miller, J., Langley, W. A., Kokko, K., Larsen, C., Zheng, N.-Y., Mays, I., Garman, L., Helms, C., et al. (2008) · Nature · doi:10.1038/nature06890 · Cited by 1,025
The rgp120 HIV Vaccine Study Group (2005) · The Journal of Infectious Diseases · doi:10.1086/428404 · Cited by 952
Fc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 901
Kwong, P. D., Doyle, M. L., Casper, D. J., Cicala, C., Leavitt, S. A., Majeed, S., Steenbeke, T. D., Venturi, M., Chaiken, I., Fung, M., et al. (2002) · Nature · doi:10.1038/nature01188 · Cited by 889
Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., van Griensven, F., Hu, D., Tappero, J. W., Choopanya, K., & Bangkok Vaccine Evaluation Group (2006) · The Journal of Infectious Diseases · doi:10.1086/508748 · Cited by 847
Self-citationDiversity Considerations in HIV-1 Vaccine Selection
Gaschen, B., Taylor, J., Yusim, K., Foley, B., Gao, F., Lang, D., Novitsky, V., Haynes, B., Hahn, B. H., Bhattacharya, T., et al. (2002) · Science · doi:10.1126/science.1070441 · Cited by 811
Self-citationHIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
McElrath, M. J., De Rosa, S. C., Moodie, Z., Dubey, S., Kierstead, L., Janes, H., Defawe, O. D., Carter, D. K., Hural, J., Akondy, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61592-5 · Cited by 713
Self-citationSeaman, M. S., Janes, H., Hawkins, N., Grandpre, L. E., Devoy, C., Giri, A., Coffey, R. T., Harris, L., Wood, B., Daniels, M. G., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02108-09 · Cited by 632
Self-citationHessell, A. J., Poignard, P., Hunter, M., Hangartner, L., Tehrani, D. M., Bleeker, W. K., Parren, P. W. H. I., Marx, P. A., & Burton, D. R. (2009) · Nature Medicine · doi:10.1038/nm.1974 · Cited by 546
Shibata, R., Igarashi, T., Haigwood, N., Buckler–White, A., Ogert, R., Ross, W., Willey, R., Cho, M. W., & Martin, M. A. (1999) · Nature Medicine · doi:10.1038/5568 · Cited by 539
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
Stamatatos, L., Morris, L., Burton, D. R., & Mascola, J. R. (2009) · Nature Medicine · doi:10.1038/nm.1949 · Cited by 430
Bonsignori, M., Hwang, K.-K., Chen, X., Tsao, C.-Y., Morris, L., Gray, E., Marshall, D. J., Crump, J. A., Kapiga, S. H., Sam, N. E., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05045-11 · Cited by 423
Self-citationThe Role of Antibodies in HIV Vaccines
Mascola, J. R., & Montefiori, D. C. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101256 · Cited by 388
Self-citationNature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1
Moore, P. L., Crooks, E. T., Porter, L., Zhu, P., Cayanan, C. S., Grise, H., Corcoran, P., Zwick, M. B., Franti, M., Morris, L., et al. (2006) · Journal of Virology · doi:10.1128/jvi.80.5.2515-2528.2006 · Cited by 343
Folks, T., Benn, S., Rabson, A., Theodore, T., Hoggan, M. D., Martin, M., Lightfoote, M., & Sell, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.13.4539 · Cited by 318
Bomsel, M., Heyman, M., Hocini, H., Lagaye, S., Belec, L., Dupont, C., & Desgranges, C. (1998) · Immunity · doi:10.1016/s1074-7613(00)80610-x · Cited by 299
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men
Li, H., Bar, K. J., Wang, S., Decker, J. M., Chen, Y., Sun, C., Salazar-Gonzalez, J. F., Salazar, M. G., Learn, G. H., Morgan, C. J., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000890 · Cited by 297
Self-citationBaum, L. L., Cassutt, K. J., Knigge, K., Khattri, R., Margolick, J., Rinaldo, C., Kleeberger, C. A., Nishanian, P., Henrard, D. R., & Phair, J. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.5.2168 · Cited by 271
Liao, H.-X., Levesque, M. C., Nagel, A., Dixon, A., Zhang, R., Walter, E., Parks, R., Whitesides, J., Marshall, D. J., Hwang, K.-K., et al. (2009) · Journal of Virological Methods · doi:10.1016/j.jviromet.2009.02.014 · Cited by 255
Self-citationLai, S. K., Hida, K., Shukair, S., Wang, Y.-Y., Figueiredo, A., Cone, R., Hope, T. J., & Hanes, J. (2009) · Journal of Virology · doi:10.1128/jvi.01899-08 · Cited by 251
Moore, P. L., Ranchobe, N., Lambson, B. E., Gray, E. S., Cave, E., Abrahams, M.-R., Bandawe, G., Mlisana, K., Abdool Karim, S. S., Williamson, C., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000598 · Cited by 233
Forthal, D. N., Landucci, G., & Daar, E. S. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6953-6961.2001 · Cited by 220
Edmonds, T. G., Ding, H., Yuan, X., Wei, Q., Smith, K. S., Conway, J. A., Wieczorek, L., Brown, B., Polonis, V., West, J. T., et al. (2010) · Virology · doi:10.1016/j.virol.2010.08.028 · Cited by 192
Self-citationWhite, T. A., Bartesaghi, A., Borgnia, M. J., Meyerson, J. R., de la Cruz, M. J. V., Bess, J. W., Nandwani, R., Hoxie, J. A., Lifson, J. D., Milne, J. L. S., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001249 · Cited by 167
Moody, M. A., Zhang, R., Walter, E. B., Woods, C. W., Ginsburg, G. S., McClain, M. T., Denny, T. N., Chen, X., Munshaw, S., Marshall, D. J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025797 · Cited by 165
Self-citationNitayaphan, S., Pitisuttithum, P., Karnasuta, C., Eamsila, C., de Souza, M. S., Morgan, P., Polonis, V. R., Benenson, M. W., VanCott, T., Ratto‐Kim, S., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/422258 · Cited by 139
Self-citationGilbert, P. B., Wang, M., Wrin, T., Petropoulos, C., Gurwith, M., Sinangil, F., D’Souza, P., Rodriguez-Chavez, I. R., deCamp, A. C., Giganti, M., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/654816 · Cited by 132
Self-citationPhase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120
Russell, N. D., Graham, B. S., Keefer, M. C., McElrath, M. J., Self, S. G., Weinhold, K. J., Montefiori, D. C., Ferrari, G., Horton, H., Tomaras, G. D., et al. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000248356.48501.ff · Cited by 105
Self-citationToward an Antibody-Based HIV-1 Vaccine
Hoxie, J. A. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.042507.164323 · Cited by 102
Karnasuta, C., Paris, R., Cox, J. H., Nitayaphan, S., Pitisuttithum, P., D, P. T. M., Brown, A. E., Gurunathan, S., Tartaglia, J., Heyward, W. L., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.10.028 · Cited by 101
Self-citationTodd, C. A., Greene, K., Yu, X., Ozaki, D. A., Gao, H., Huang, Y., Wang, M., Li, G., Brown, R., Wood, B., et al. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.09.007 · Cited by 82
Self-citationAdvancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.
Francis, D. P., Gregory, T. J., McElrath, M. J., Belshe, R. B., Gorse, G. J., Migasena, S., Kitayaporn, D., Pitisuttitham, P., Matthews, T. J., Schwartz, D. H., et al. (1998) · PubMed · Cited by 73
Self-citationIncreased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration
Choudhry, V., Zhang, M.-Y., Harris, I., Sidorov, I. A., Vu, B. K., Dimitrov, A. S., FOUTS, T. R., & Dimitrov, D. S. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.07.163 · Cited by 59
Crooks, E. T., Moore, P. L., Richman, D. D., Robinson, J. E., Crooks, J. A., Franti, M., Schülke, N., & Binley, J. Μ. (2006) · Human Antibodies · doi:10.3233/hab-2005-143-407 · Cited by 57
Huang, Y., Gilbert, P. B., Montefiori, D. C., & Self, S. G. (2009) · Statistics in Biopharmaceutical Research · doi:10.1198/sbr.2009.0008 · Cited by 45
Self-citationCleghorn, F. R., Pape, J. W., Schechter, M., Bartholomew, C., Sanchez, J., Jack, N., Metch, B. J., Hansen, M., Allen, M., Cao, H., et al. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318149297d · Cited by 31
Self-citation
Cited by
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Liao, H.-X., Lynch, R., Zhou, T., Gao, F., Alam, S. M., Boyd, S. D., Fire, A. Z., Roskin, K. M., Schramm, C. A., Zhang, Z., et al. (2013) · Nature · doi:10.1038/nature12053 · Cited by 988
Self-citationSanders, R. W., Derking, R., Cupo, A., Julien, J.-P., Yasmeen, A., de Val, N., Kim, H. J., Blattner, C., de la Peña, A. T., Korzun, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003618 · Cited by 935
Pardi, N., Hogan, M. J., Naradikian, M. S., Parkhouse, K., Cain, D. W., Jones, L., Moody, M. A., Verkerke, H. P., Myles, A., Willis, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171450 · Cited by 530
Self-citationSarzotti-Kelsoe, M., Bailer, R. T., Turk, E., Lin, C.-L., Bilska, M., Greene, K. M., Gao, H., Todd, C. A., Ozaki, D. A., Seaman, M. S., et al. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.11.022 · Cited by 532
Self-citationHIV‐1 neutralizing antibodies: understanding nature's pathways
Mascola, J. R., & Haynes, B. F. (2013) · Immunological Reviews · doi:10.1111/imr.12075 · Cited by 475
Self-citation
Metadata
- Authors
- Montefiori, D. C., Karnasuta, C., Huang, Y., Ahmed, H., Gilbert, P., de Souza, M. S., McLinden, R., Tovanabutra, S., Laurence-Chenine, A., Sanders-Buell, E., Moody, M. A., Bonsignori, M., Ochsenbauer, C., Kappes, J., Tang, H., Greene, K., Gao, H., LaBranche, C. C., Andrews, C., Polonis, V. R., Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Self, S. G., Berman, P. W., Francis, D., Sinangil, F., Lee, C., Tartaglia, J., Robb, M. L., Haynes, B. F., Michael, N. L., & Kim, J. H.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-05-25
- Volume
- 206
- Issue
- 3
- Pages
- 431-441
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2108823547
- Cited by
- 284
- References
- 45
- FWCI
- 17.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.